简体中文 | 繁體中文 | English

Health and Pharmaceutical Press Releases

2024-03-11 11:35 Galderma @ AAD 2024: New Data Demonstrate the Long-Term Efficacy of Nemolizumab in Prurigo Nodularis and Its Durability in Atopic Dermatitis
2024-03-08 14:35 C₂N Diagnostics, LLC Announces Investment From Eisai Inc.
2024-03-08 13:16 The World does not yet Know the Power of Natto: “Natto Power - Japanese Fermented Food Natto, the key to Better Living -”
2024-03-08 10:36 Two Year Sustained Cognitive Benefits of Hydromethylthionine Mesylate (HMTM) Indicated by TauRx's LUCIDITY Trial
2024-03-04 12:02 Wellness Market Leaders Join Forces: The DRIPBaR Powered by REVIV
2024-03-01 20:51 Japan Hosted a Conference to Boost Ukraine’s Economic Growth and Recovery
2024-03-01 11:38 Kenai Therapeutics Announces $82 Million Series A Financing to Advance Next Generation Allogeneic Cell Therapies for Neurological Diseases
2024-02-29 16:52 Galderma Announces Record 2023 Net Sales of Over 4 B USD and Significant Core EBITDA Margin Expansion
2024-02-29 11:42 Medidata and Sanofi Vaccines Extend Collaboration to Improve Patient Centricity and Trial Efficiency
2024-02-29 11:01 BeiGene Reports Fourth Quarter and Full Year 2023 Financial Results and Business Updates
2024-02-28 14:55 Galderma to Showcase Latest Updates From Its Broad, Innovative and Leading Dermatology Portfolio at the 2024 American Academy of Dermatology Annual Meeting
2024-02-28 14:11 BeiGene Receives Positive CHMP Opinion for Tislelizumab as Treatment for Non-Small Cell Lung Cancer
2024-02-28 13:56 Takeda and Biological E. Limited Collaborate to Accelerate Access to Dengue Vaccine in Endemic Areas
2024-02-28 13:46 ReNAgade Therapeutics Appoints Joe Bolen, Ph.D., Chief Science Innovation Officer
2024-02-27 12:55 MHRA Issues Notice of Acceptance for POLARIS-AD, a Phase 3 Early Alzheimer’s Disease Trial Sponsored by AriBio Co., Ltd.
2024-02-27 12:09 Caldera Medical's Humanitarian Effort Reaches New Heights: 400,000 Women Treated Worldwide
2024-02-26 09:44 Celltrion presents new two-year data for subcutaneous infliximab (CT-P13 SC) in inflammatory bowel disease (IBD) at the 19th ECCO Congress
2024-02-26 09:37 Neuraptive Therapeutics, Inc. Announces Positive 24-Week Data for NTX-001 in the Phase 2 NEUROFUSE Study, Reinforcing Previously Announced Proof of Concept 12-Week Data
2024-02-23 11:41 New Swiss Made Features for Cataract Surgery Lens Selection
2024-02-23 11:18 ReNAgade Therapeutics to Present at the Evercore ISI 2024 Emerging Biotech Conference

Business Wire Weibo

Press Releases

Latest Releases